Neo Immune Tech's CEO, Sehwan Yang, disclosed on December 12th a pivotal research collaboration with Imugen, an Australian-based biotech firm. Under this agreement, Neo Immune Tech will supply 'NT-I7' (developmental codename) to Imugen, who will integrate it into their CAR-T therapy 'Azer-cell.'

Imugen, a listed biotech company on the Australian Securities Exchange, focuses on developing diverse immunotherapies for various cancer stages. Their pipeline includes 'azer-cel,' an advanced CAR-T therapy, 'CF33' - an oncolytic virus therapy, and a B-cell vaccine candidate for immunotherapy. Notably, the CF33 treatment 'VAXINIA' received accelerated review status from the U.S. FDA.

Leslie Chong, Imugen's CEO, expressed enthusiasm about the collaboration, stating, "Collaborating with Neo Immune Tech holds promise to enhance the efficacy of azer-cel."

Sehwan Yang, CEO of Neo Immune Tech, highlighted, "NT-I7 has demonstrated promising results across immune-oncology and infectious diseases." He added, "Our collaboration with Imugen, a key player in allogeneic cell therapy, aims to amplify the potential of NT-I7 and expedite its market introduction."

A Neo Immune Tech representative revealed, "Since mid-this year, we've invested in NT-I7 production and signed material supply pacts with six firms, including this latest agreement." They continued, "Expanding NT-I7 supply to global biotech firms aims to establish T-cell amplifiers as a benchmark in immune-oncology, empowering our partners' therapies to achieve heightened competitiveness."